Skip to content
Levamisole
Ergamisol (levamisole) is a small molecule pharmaceutical. Levamisole was first approved as Ergamisol on 1990-06-18. It is used to treat colonic neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levamisole hydrochloride
Tradename
Company
Number
Date
Products
ERGAMISOLJohnson & JohnsonN-020035 DISCN1990-06-18
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colonic neoplasmsD003110C18
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
P02: Anthelmintics
P02C: Antinematodal agents
P02CE: Imidazothiazole derivatives, antinematodal
P02CE01: Levamisole
HCPCS
Code
Description
S0177
Levamisole hydrochloride, oral, 50 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVAMISOLE
INNlevamisole
Description
Levamisole is a 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine. It has a role as an antinematodal drug, an antirheumatic drug, an immunomodulator, an immunological adjuvant and an EC 3.1.3.1 (alkaline phosphatase) inhibitor. It is an enantiomer of a dexamisole.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
c1ccc([C@H]2CN3CCSC3=N2)cc1
Identifiers
PDB
CAS-ID14769-73-4
RxCUI6371
ChEMBL IDCHEMBL1454
ChEBI ID6432
PubChem CID26879
DrugBankDB00848
UNII ID2880D3468G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 9,610 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2 adverse events reported
View more details